Compare Atomera Incorporated (ATOM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atomera Incorporated vs Medpace Holdings Inc — how do they compare? Atomera Incorporated trades at $6.48 (market cap $247.40M), while Medpace Holdings Inc trades at $536.29 (market cap $15.31B). The key difference: Medpace Holdings Inc is far larger — about 61.9× Atomera Incorporated's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Atomera Incorporated nearer its low. Which is the better fit depends on your goals.
| ATOM | MEDP | |
|---|---|---|
Market Cap | $247.40M | $15.31B |
Sector | Technology | Technology |
52-Week High | $12.11 | $620.59 |
52-Week Low | $1.99 | $308.88 |
Enterprise Value | $207.61M | $14.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $6.25, down 5.73% over 24 hours, reflecting a bearish technical outlook with negative earnings trends. The company reported a net loss of $20.17 million in 2025 on minimal revenue of $65,000, with profitability metrics deeply negative. Recent news highlights Atomera's focus on semiconductor technology advancements, including GaN-on-Silicon collaborations, but financial performance remains a significant concern.
The outlook is cautious due to persistent losses and weak revenue, though analyst consensus is unanimously bullish with a 100% buy rating. Key risks include execution challenges in monetizing technology and high cash burn. Upside depends on successful commercialization of its semiconductor IP, but current fundamentals suggest high volatility and substantial shareholder risk.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
